



FOR IMMEDIATE RELEASE

Vita Global Sciences Partners with Veeva to Streamline Clinical Data Management

CRO will use Veeva Vault EDC to deliver a better experience to patients, research sites, and sponsors

PLEASANTON, CA — June 19, 2024 — **Veeva Systems** (NYSE: VEEV) today announced that Vita Global Sciences is partnering with Veeva to modernize its clinical data management processes and improve collaboration with key trial stakeholders. With **Veeva Vault EDC**, the CRO is establishing a foundation for study efficiency and faster study builds.

"Veeva Vault EDC allows us to simplify our processes while ensuring a seamless experience for patients, research sites, and sponsors," said Kelly Forester, director of clinical data management at Vita Global Sciences. "Partnering with Veeva advances our mission to deliver innovations that can profoundly impact patient lives."

The CRO will use Vault EDC to design and deliver complex studies for its sponsor clients. Looking ahead, Vita Global Sciences plans to add **Veeva Clinical Database (CDB)** to aggregate and clean data from all sources, and **Veeva RTSM** to randomize patients and optimize trial supply management. This ensures Vita Global Sciences can run the study clients want while gaining visibility and control of trial data. With modern clinical data management applications on a single platform, the company can reduce manual processes for improved accuracy and speed.

"Veeva Vault EDC will help advance Vita Global Sciences processes as they move toward the future of clinical trials," said Jon Young, director, Veeva Vault Clinical Data Management strategy. "By establishing a clinical data foundation, Vita Global Sciences can accelerate study builds and manage changes with no downtime for faster trials that can improve patient outcomes."

Vault EDC is part of **Veeva Vault Clinical Data Management**, bringing together EDC and Veeva CDB for next-generation clinical data management. To learn more, visit veeva.com/VaultClinicalDataManagement.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a **Public Benefit Corporation**, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find [here](#) (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov.

###

Contact:

Deivis Mercado

Veeva Systems
925-226-8821
deivis.mercado@veeva.com